GCB-27a
GCB-27a is a CD1d-binding immunostimulant and antitumor agent. GCB-27a binds to CD1d to form a stable complex and presents it to NKT cells, enhancing hydrophobic interactions within the A' pocket of CD1d through branched-chain conformation restriction. GCB-27a induces a Th1-biased immune response, drives IFN?γ production and limits IL-4 levels. GCB-27a is applicable to research related to melanoma lung metastasis.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Formule: C52H95NO10
- Masse moléculaire:894.31
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
GCB-27a (1-1000 nM; 72 h) potently stimulates Th1-biased cytokine production in C57BL/6 mouse splenocytes in vitro, with elevated IFN-γ secretion across all tested concentrations and no associated cytotoxicity[1].
GCB-27a (100 nM; 2-24 h) forms more stable and sustained complexes with mouse CD1d on BMDC surfaces than αGalCer, as measured by enhanced and prolonged L363 antibody binding[1].
GCB-27a (24 h) potently induces Th1-biased cytokine production in human NKT cells, with a 2-fold higher frequency of IFN-γ+ cells than αGalCer and comparable IL-4 induction[1].
GCB-27a has stronger binding affinity for both human and murine CD1d than αGalCer, due to optimized hydrophobic interactions and conformational preorganization within the CD1d A' pocket[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
GCB-27a (2.33 nmol per mouse; i.p.; single injection) potently activates innate immune cells in C57BL/6 mice, enhancing DC maturation marker expression and increasing the frequency of IFN-γ-secreting NK cells[1].
GCB-27a (0.58 nmol per mouse; i.p.; single injection) exhibits potent antitumor efficacy in a murine melanoma lung metastasis model, reducing metastatic nodule counts by 89% relative to αGalCer via a sustained Th1-biased immune response[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c mice (n=5)[1]
-
Dosage:2.33 nmol per mouse
-
Administration:i.p.; single injection
-
Result:Induced a 10.9-fold increase in serum IFN-γ levels relative to αGalCer at 24 hours post-injection.
Maintained IL-4 levels comparable to those induced by αGalCer.
Demonstrated the strongest Th1 selectivity among all tested analogs, with the highest IFN-γ/IL-4 ratio fold change over αGalCer.
Confirmed sustained Th1-biased activity via time-dependent cytokine analysis, with peak IFN-γ levels observed at 24 hours post-injection.
-
Animal Model:C57BL/6 mice (n=3)[1]
-
Dosage:2.33 nmol per mouse
-
Administration:i.p.; single injection
-
Result:Markedly increased CD80 and CD86 expression on CD11c+ DCs relative to αGalCer.
Elevated the frequency of IFN-γ-producing NK cells to ~20% of splenic NK cells, a significant increase compared to αGalCer.
-
Animal Model:C57BL/6 mice (n=6; melanoma lung metastasis model)[1]
-
Dosage:0.58 nmol per mouse
-
Administration:i.p.; single injection
-
Result:Elicited significantly elevated serum IFN-γ levels relative to αGalCer, while IL-4 levels remained comparable to αGalCer.
Achieved an 89% decrease in lung metastatic nodule counts relative to the αGalCer-treated group.
Revealed near-complete inhibition of lung metastasis via histological analysis.
Chemical Information
-
Masse moléculaire 894.31
-
Formule C52H95NO10
-
SMILES
O[C@H]1[C@@H](CO)O[C@H](OC[C@H](NC(CC2=CC=C(OCC(CCCCCCCC)CCCCCCCCCC)C=C2)=O)[C@H](O)[C@H](O)CCCCCCCCCCCCCC)[C@H](O)[C@H]1O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz